Physician profile
Seth Brum
NPI 1144271917
$294,393.54
in general payments reported to CMS, 2019-2025
55 companies · $23K in 2025
The $23K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $55K · 2020: $48K · 2021: $50K · 2022: $58K · 2023: $34K · 2024: $26K · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $71K · Food and Beverage: $9,806 · Travel and Lodging: $1,694 · Education: $11.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $71,259.75 |
| Food and Beverage | $9,805.92 |
| Travel and Lodging | $1,693.89 |
| Education | $11.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $110,776.70 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $100,863.08 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Allergan, INC. | $57,258.96 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $10,288.70 | 2019-2025 | Spravato |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $5,509.14 | 2019-2025 | Xifaxan, Trulance |
| Astrazeneca Pharmaceuticals LP | $2,307.74 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $933.97 | 2021-2025 | |
| Pfizer INC. | $883.73 | 2019-2025 | |
| Glaxosmithkline, LLC. | $647.33 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $618.48 | 2019-2025 | Uplizna, Evenity, Prolia |
| Otsuka America Pharmaceutical, INC. | $420.68 | 2022-2025 | Rexulti, Abilify Maintena |
| Lilly USA, LLC | $409.43 | 2019-2024 | Mounjaro, Trulicity, Zepbound |
| Teva Pharmaceuticals USA, INC. | $329.59 | 2019-2023 | Austedo |
| Merck Sharp & Dohme LLC | $259.15 | 2019-2023 | Steglatro, Verquvo, Belsomra |
| Abbott Laboratories | $255.38 | 2021-2024 | Freestyle Libre 3 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seth Brum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.